Colorectal carcinoma (CRC) was traditionally thought of
|
|
- Ruth Palmer
- 5 years ago
- Views:
Transcription
1 Testing for Defective DNA Mismatch Repair in Colorectal Carcinoma A Practical Guide Lawrence J. Burgart, MD Context. Significant bench and clinical data have been generated during the last decade regarding DNA mismatch repair in colorectal carcinoma. Objectives. To review clinically relevant aspects of defective DNA mismatch repair in colorectal carcinoma and to suggest testing algorithms for identification of these tumors in the sporadic and familial settings. Data Sources. This article is based on literature review and clinical testing experience of more than 2000 patient samples. Conclusions. Approximately 15% of colorectal carcinomas arise as a result of defective DNA mismatch repair. Ninety percent of these carcinomas are sporadic, arising as a result of methylation of the MLH1 gene promoter, silencing expression. These sporadic carcinomas have improved stage-specific prognosis and can be identified by demonstrating aberrant loss of expression with an MLH1 immunoperoxidase stain. Familial colorectal carcinomas with defective DNA mismatch repair (Lynch syndrome) are due to a germline defect in one of several DNA mismatch repair genes. The familial carcinomas are best identified with a combination of immunohistochemistry and molecular microsatellite analysis. This testing facilitates subsequent directed genetic testing of the proband and family members. (Arch Pathol Lab Med. 2005;129: ) Colorectal carcinoma (CRC) was traditionally thought of as a monolithic disease process. During the last decade, however, variability in the underlying genetic pathogenesis has been described and has become clinically relevant. 1 Colon cancer can now be split into (at least) 2 subsets based on molecular pathogenesis, the first characterized by chromosome instability and the second by genomic (genome-wide) instability. The chromosomal instability (CIN) pathway accounts for 80% to 85% of all colon cancers. The CIN pathway involves loss of tumor suppressor genes and activation of oncogenes, characteristically identified as loss of heterozygosity, and often manifests overt aneuploidy. Commonly involved genes include the adenomatous polyposis coli (APC) gene, K-ras, the deleted in colon cancer (DCC) locus, and p53. This pathway also underlies familial adenomatous polyposis, which accounts for approximately 0.5% of all colon cancers. This large group probably comprises at least 2 major subsets likely to become better understood in the next several years. 2 Genomic instability results from a loss of DNA mismatch repair (MMR) activity. 3 Normal DNA synthesis is associated with a low but finite error rate in terms of which nucleotide is put into the daughter strand, or when- Accepted for publication July 12, From the Mayo Clinic, Rochester, Minn. The author has no relevant financial interest in the products or companies described in this article. Corresponding author: Lawrence J. Burgart, MD, Abbott NW Hospital, 800 E 28th St, Minneapolis, MN ( lawrence. burgart@allina.com). Reprints not available from the author. ever a base is added or deleted. It is, of course, critical to have a high-fidelity repair system to maintain the integrity of the genetic code. One of these repair systems is a family of proteins that works together as the DNA MMR complex. These genes/proteins have unfortunate alpha-numeric names, with the 4 major genes being MLH1, MSH2, PMS2, and MSH6. If any one of these proteins is absent, DNA MMR function is severely compromised. In the absence of DNA MMR activity, genome-wide mutations quickly accrue over the course of several generations of cell division (schematically represented in Figure 1). DNA microsatellites (mononucleotide, dinucleotide, or tetranucleotide repeat sequences found throughout the genome) make excellent test sites to assay for genetic errors that occur as a result of defective DNA MMR. Accordingly, the standard molecular laboratory test for defective DNA MMR is amplification of several microsatellites to look for abnormal variation in length, which is referred to as microsatellite instability (MSI). MICROSATELLITE INSTABILITY IS AN EXQUISITELY SENSITIVE AND SPECIFIC MARKER FOR DEFECTIVE DNA MMR Defective DNA MMR accounts for 15% to 20% of sporadic colon cancers, which typically occur at an older age than sporadic CIN carcinomas, are more frequently present in the proximal colon, and affect women twice as often as men. Lynch syndrome is a familial syndrome due to heritable defective DNA MMR that accounts for 2% of all colon cancers, demonstrates autosomal-dominant inheritance, has no gender bias, and has a broad age distribution with peak in the fifth decade. Sporadic colon cancer with defective DNA MMR is es- Arch Pathol Lab Med Vol 129, November 2005 DNA Mismatch Repair in Colorectal Carcinoma Burgart 1385
2 1386 Arch Pathol Lab Med Vol 129, November 2005 DNA Mismatch Repair in Colorectal Carcinoma Burgart
3 sentially always due to the same, very specific DNA alteration. 4 All of these MSI-positive CRCs result from methylation of the MLH1 gene promoter, which stops transcription of both MLH1 alleles. Therefore, not only do all sporadic CRCs due to defective DNA MMR have MSI, but they also are essentially all due to lack of MLH1 expression. Based on the above discussion, CRCs can be divided into 4 subtypes (schematically represented in Figure 2): (1) familial colon cancer due to chromosomal stability (familial adenomatous polyposis), (2) sporadic colon cancers due to CIN (ordinary-type colon cancer), (3) familial colon cancer due to defective DNA MMR (Lynch syndrome), and (4) sporadic colon cancer due to defective DNA MMR. IS IT IMPORTANT TO IDENTIFY SPORADIC CRC DUE TO DEFECTIVE DNA MMR? Sporadic colon cancers with defective DNA MMR have a significantly improved prognosis over CIN-pathway CRCs. 5 7 In fact, stage III CRCs with defective DNA MMR have a survival curve superimposable on that of stage II CIN cancers. This equates to half as much mortality in stage III CRC with defective DNA MMR through stage II CRC with CIN. Unfortunately, there are few data on whether this is dependent or independent of treatment, and the available data are conflicting Currently, treatment decisions are not made based on DNA MMR status, despite in vitro data suggesting that 5-FU based therapies do not work in these cancers. 9,11 15 However, as chemotherapeutic regimens become refined and as panels of prognostic markers are put in place to determine which stage II and III CRC patients should receive therapy, these data will become essential. IF MY CLINICIANS ARE INTERESTED IN THIS PROGNOSTIC INFORMATION, WHAT IS THE BEST TEST TO PERFORM? The candidate tests for detection of defective DNA MMR in colon cancer include histology, immunohistochemistry, and molecular MSI testing. Characteristic histologic features do exist for CRC with defective DNA MMR. 16,17 The most specific morphologic feature is a cribriform/solid (medullary) architecture without anaplastic cytology (Figure 3). Mucinous colon cancers (colloid and signet ring) also have an increased incidence of defective DNA MMR, but are much less specific than the medullary pattern. The suboptimal aspect of using the cribriform/ solid architectural pattern as a test for defective DNA MMR is poor sensitivity. The sensitivity is approximately 50%; half of all CRCs with defective DNA MMR have ordinary-type morphology with gland formation and desmoplasia. Tumor-infiltrating lymphocytes are more sensitive for the detection of defective DNA MMR. 18,19 Tumorinfiltrating lymphocytes have to be intimately associated with the colon cancer cells to count for this assessment. Figure 3. Colon carcinoma with defective DNA mismatch repair demonstrating characteristic solid/cribriform (medullary) architecture and numerous tumor-infiltrating lymphocytes (hematoxylin-eosin, original magnification 600). Figure 4. Colon carcinoma with defective DNA mismatch repair due to aberrant loss of nuclear MLH1 expression in the neoplastic cells, as demonstrated by this immunoperoxidase stain. Note the internal positive control in adjacent benign colonocytes, lamina propria stroma, and tumor-infiltrating lymphocytes (MLH1 immunoperoxidase, original magnification 400). This does not include peritumoral or Crohn-like inflammation. Unfortunately, there is a sensitivity-specificity trade-off, which results in approximately 80% sensitivity with 80% specificity when you have approximately 5 tumor-infiltrating lymphocytes per high-power field. Therefore, this is a good but not perfect marker for the detection of MSI-positive colon cancers. For sporadic CRC with defective DNA MMR, immu- Figure 1. Schematic representation of normal versus defective DNA mismatch repair. DNA replication normally has a low, finite rate of erroneous base placement in the daughter strand, which is corrected by a complex of DNA repair enzymes. If the repair mechanism is inactivated by gene mutation or promoter methylation, genomic instability results from accumulation of genome-wide mutations. Genomic instability is readily measured in the laboratory by polymerase chain reaction analysis of DNA microsatellites. Figure 2. Schematic representation of relative frequency, by age, of the major categories of familial and sporadic colorectal carcinoma. FAP indicates familial adenomatous polyposis; CIN, chromosomal instability; and MSI, colorectal carcinoma with defective DNA mismatch repair resulting in microsatellite instability. Arch Pathol Lab Med Vol 129, November 2005 DNA Mismatch Repair in Colorectal Carcinoma Burgart 1387
4 Figure 5. Approximately colorectal carcinomas are diagnosed in the United States each year. Approximately 30% of colon cancer patients have a positive family history in a first- or second-degree relative. Approximately 2% of colon cancers are due to Lynch syndrome (heritable defective DNA mismatch repair). nohistochemistry is an excellent assay (Figure 4). 3 MLH1 immunoperoxidase staining has essentially 100% sensitivity and specificity for defective DNA MMR in the sporadic setting due to the homogeneous underlying molecular pathogenesis (MLH1 promoter methylation). One would have to do this immunostain on all colon cancers to have near-100% sensitivity, but molecular microsatellite analysis would be redundant and therefore unnecessary. Immunohistochemical reagents are available for MLH1, MSH2, MSH6, and PMS2 expression. The vast majority of all cell types (except those very terminally differentiated) normally demonstrate nuclear expression of each of these DNA MMR enzymes. This provides an extremely useful internal positive control when assaying for aberrant loss of a DNA MMR protein (Figure 4). IS IT IMPORTANT TO PERFORM IMMUNOHISTOCHEMISTRY AND/OR MOLECULAR MICROSATELLITE ANALYSIS TO DETECT LYNCH SYNDROME PROBANDS? Approximately 2% of the CRCs diagnosed in the United States each year occur in patients with Lynch syndrome (Figure 5) This means there are approximately 3000 CRCs per year in Lynch syndrome families. In addition, Lynch syndrome families are at risk for endometrial, upper gastrointestinal, upper urinary tract, ovarian, and pancreaticobiliary carcinomas. Identifying these families allows for sorting of at-risk family members. This autosomal-dominant disease results in 50% of family members having an 80% to 100% lifetime risk of carcinoma development, with the other half having normal cancer risk. Therefore, identification of Lynch syndrome probands can impact decision making (eg, screening, prophylactic surgery) tremendously. It is reasonable to clarify some terminology at this point. Hereditary nonpolyposis colorectal cancer syndrome (HNPCC) is a clinically defined term based on strong family history of colon cancer. The original HNPCC definition, referred to as the Amsterdam Criteria, includes the following: (1) 3 involved relatives, 2 of whom are first-degree relatives; (2) successive generations involved; and (3) 1 involved patient younger than 50 years. In only 60% of the families with a strong family history of colorectal carcinoma, even to the extent of meeting these criteria, the colorectal carcinoma is due to heritable DNA mismatch repair. 24,25 Therefore, 40% of HNPCC families remain unexplained as to their genetic basis. Disease in those HNPCC families with heritable DNA MMR is referred to as Lynch syndrome. 21 Approximately 30% of colon cancer patients have at least 1 first- or second-degree relative also with colon cancer. Immunohistochemical findings in Lynch syndrome cases are much more complex than in sporadic MSI-positive CRCs. While 100% of Lynch syndrome related carcinomas have MSI, only approximately 95% of them will have abnormal immunohistochemistry findings (loss of expression of a DNA MMR enzyme). The rough distribution of abnormal DNA MMR gene and subsequent loss of protein expression within Lynch syndrome families is as follows: MLH1, 40%; MSH2, 40%; MSH6, 5%; and PMS2, 5%. A small percentage of Lynch syndrome families develop MSI-positive carcinomas with intact staining of all 4 of these enzymes due either to a missense mutation affecting function but not antigenicity, or involvement of another minor protein in the complex. Based on the above information, recommended testing for Lynch syndrome includes a combination of molecular microsatellite analysis and immunohistochemistry for MLH1, MSH2, PMS2, and MSH6. This allows for highsensitivity detection of MSI within the tumors and identification of which enzyme is abnormal within that family, in turn guiding the subsequent germline mutation analysis. Both microsatellite analysis and immunohistochemistry are performed on paraffin-embedded tissue. The microsatellite analysis requires both tumoral and nontumoral tissue for comparison. WHICH CRC PATIENTS SHOULD BE TESTED FOR LYNCH SYNDROME? The rule of thumb is any patient with CRC arising with positive family history and/or young age. A series of National Institutes of Health sponsored consensus conferences have established the Bethesda Guidelines for selecting patients to test Arch Pathol Lab Med Vol 129, November 2005 DNA Mismatch Repair in Colorectal Carcinoma Burgart
5 There are instances in which it can be difficult to differentiate between familial and sporadic defective DNA MMR colon cancer. For example, a 50-year-old with a colon cancer showing high levels of MSI and loss of MLH1 expression can be ambiguous as to germline versus somatic abnormality if the family history is not clear or unavailable. Germline analysis is helpful in these situations, but is also less than 100% sensitive. Recently, a specific B- raf mutation in codon 600 has been identified in a majority of sporadic (methylated) defective DNA mismatch repair CRC cases, which rarely is present in Lynch syndrome carcinomas. 26,27 Therefore, B-raf mutational analysis may soon become part of the testing algorithm in this situation. In summary, 15% to 20% of CRCs are due to defective DNA MMR. Ninety percent of these cases will be caused by silencing of MLH1 expression due to methylation of the gene promotor. These sporadic CRCs with defective DNA MMR have a significantly improved prognosis, but therapy is unchanged. Lynch syndrome proband identification is a very active testing program taking advantage of both microsatellite analysis and immunohistochemistry on paraffin-embedded tissue with subsequent gene mutation analysis (peripheral blood DNA) to sort at-risk family members. References 1. Hamilton SR. The molecular genetics of colorectal neoplasia. Gastroenterology. 1993;105: Burgart LJ. Colorectal polyps and other precursor lesions: need for an expanded view. Gastroenterol Clin North Am. 2002;31: Thibodeau SN, French AJ, Cunningham JM, et al. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hmlh1. Cancer Res. 1998;58: Cunningham JM, Christensen ER, Tester DJ, et al. Hypermethylation of the hmlh1 promoter in colon cancer with microsatellite instability. Cancer Res. 1998;58: Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA, Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology. 2000;119: Coleman LW, Curtin K, Schaffer D, Leppert M, Slattery ML, Samowitz WS. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Mod Pathol. 2001;14:83A. 7. Parc Y, Gueroult S, Mourra N, et al. Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer. Gut. 2004;53: Elsaleh H, Joseph D, Grieu F, et al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet. 2000; 355: Claij N, te Riele H. Microsatellite instability in human cancer: a prognostic marker for chemotherapy? Exp Cell Res. 1999;246: Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349: Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res. 1998;4: Anthony DA, McIlwrath AJ, Gallagher WM, Edin AR, Brown R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res. 1996;56: Kat A, Thilly WG, Fank W-H, et al. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci U S A. 1993;90: Branch P, Aquilina G, Bignami M, Karran P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature. 1993;362: Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA. Role of the hmlh1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res. 2001;61: Kim H, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol. 1994;145: Krishna M, Burgart LJ, French AJ, Moon-Tasson L, Halling KC, Thibodeau SN. Histopathologic features associated with microsatellite instability in colorectal carcinomas. Gastroenterology. 1996;110:A Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer. 2001;91: Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathologic identification of colon cancer with microsatellite instability. Am J Pathol. 2001;158: Mecklin J-P, Järvinin H, Hakkiluoto A, et al. Frequency of hereditary nonpolyposis colorectal cancer: a prospective multicenter study in Finland. Dis Colon Rectum. 1995;38: Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96: Lynch HT, Smyrk TC, Watson P, et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology. 1993;104: Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352: Kievit W, de Bruin JH, Adang EM, et al. Current clinical selection strategies for identification of hereditary non-polyposis colorectal cancer families are inadequate: a meta-analysis. Clin Genet. 2004;65: Lipton LR, Johnson V, Cummings C, et al. Refining the Amsterdam Criteria and Bethesda Guidelines: testing algorithms for the prediction of mismatch repair mutation status in the familial cancer clinic [published correction appears in J Clin Oncol. 2005;23:3652]. J Clin Oncol. 2004;22: Domingo E, Laiho P, Ollikainen M, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet. 2004;41: McGivern A, Wynter CV, Whitehall VL, et al. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer. 2004;3: Arch Pathol Lab Med Vol 129, November 2005 DNA Mismatch Repair in Colorectal Carcinoma Burgart 1389
A Review from the Genetic Counselor s Perspective
: A Review from the Genetic Counselor s Perspective Erin Sutcliffe, MS, CGC Certified Genetic Counselor Cancer Risk Evaluation Program INTRODUCTION Errors in base pair matching that occur during DNA replication,
More informationDevelopment of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationMeasure Description. Denominator Statement
CMS ID/CMS QCDR ID: CAP 18 Title: Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing to Inform Clinical Management and Treatment Decisions in Patients with Primary or Metastatic
More informationGuidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer
Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer Start date: May 2015 Review date: April 2018 1 Background Mismatch repair (MMR) deficiency is seen in approximately 15%
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer January 2015 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationCOLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer
COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer March 2017 1 Background Mismatch repair (MMR) deficiency is seen in approximately
More informationUniversal Screening for Lynch Syndrome
Universal Screening for Lynch Syndrome St. Vincent/Ameripath protocol proposal Lynch syndrome (HNPCC) 1/35 individuals with colorectal cancer has Lynch syndrome Over half individuals are >50 at time of
More informationGENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By. Magnitude of the Problem. Magnitude of the Problem. Cardinal Features of Lynch Syndrome
GENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By HENRY T. LYNCH, M.D. 1 Could this be hereditary Colon Cancer 4 Creighton University School of Medicine Omaha, Nebraska Magnitude of the Problem Annual
More informationSerrated Polyps and a Classification of Colorectal Cancer
Serrated Polyps and a Classification of Colorectal Cancer Ian Chandler June 2011 Structure Serrated polyps and cancer Molecular biology The Jass classification The familiar but oversimplified Vogelsteingram
More informationClinicopathologic Characteristics of Left-Sided Colon Cancers with High Microsatellite Instability
The Korean Journal of Pathology 29; 43: 428-34 DOI: 1.4132/KoreanJPathol.29.43.5.428 Clinicopathologic Characteristics of Left-Sided Colon Cancers with High Microsatellite Instability Sang Kyum Kim Junjeong
More informationClinicopathologic Factors Identify Sporadic Mismatch Repair Defective Colon Cancers
Anatomic Pathology / MORPHOLOGY IN MMR-DEFECTIVE COLON CANCER Clinicopathologic Factors Identify Sporadic Mismatch Repair Defective Colon Cancers Britta Halvarsson, MD, PhD, 1 Harald Anderson, PhD, 2 Katarina
More informationThe Whys OAP Annual Meeting CCO Symposium September 20. Immunohistochemical Assessment Dr. Terence Colgan Mount Sinai Hospital, Toronto
Immunohistochemical Assessment of Mismatch Repair Proteins in Endometrial Cancer: The Whys and How Terence J. Colgan, MD Head of Gynaecological Pathology, Mount Sinai Hospital, University of Toronto, Toronto.
More informationHigh risk stage II colon cancer
High risk stage II colon cancer Joel Gingerich, MD, FRCPC Assistant Professor Medical Oncologist University of Manitoba CancerCare Manitoba Disclaimer No conflict of interests 16 October 2010 Overview
More informationCAP Laboratory Improvement Programs. Summary of Microsatellite Instability Test Results From Laboratories Participating in Proficiency Surveys
CAP Laboratory Improvement Programs Summary of Microsatellite Instability Test Results From Laboratories Participating in Proficiency Surveys Proficiency Survey Results From 2005 to 2012 Theresa A. Boyle,
More informationCase Presentation Diana Lim, MBBS, FRCPA, FRCPath Senior Consultant Department of Pathology, National University Health System, Singapore Assistant Pr
Case Presentation Diana Lim, MBBS, FRCPA, FRCPath Senior Consultant Department of Pathology, National University Health System, Singapore Assistant Professor Yong Loo Lin School of Medicine, National University
More informationLynch Syndrome Screening for Endometrial Cancer: Basic Concepts 1/16/2017
1 Hi, my name is Sarah Kerr. I m a pathologist at Mayo Clinic, where I participate in our high volume Lynch syndrome tumor testing practice. Today I hope to cover some of the basics needed to understand
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationColorectal cancer Chapelle, J Clin Oncol, 2010
Colorectal cancer Chapelle, J Clin Oncol, 2010 Early-Stage Colorectal cancer: Microsatellite instability, multigene assay & emerging molecular strategy Asit Paul, MD, PhD 11/24/15 Mr. X: A 50 yo asymptomatic
More informationLynch Syndrome. Angie Strang, PGY2
Lynch Syndrome Angie Strang, PGY2 Background Previously hereditary nonpolyposis colorectal cancer Autosomal dominant inherited cancer susceptibility syndrome Caused by defects in the mismatch repair system
More informationTumorNext-Lynch. genetic testing for hereditary colorectal or uterine cancer
TumorNet-Lynch genetic testing for hereditary colorectal or uterine cancer What Are the Causes of Hereditary Colorectal Cancer? sporadic 70% familial 20% hereditary 10% Lynch syndrome, up to 4% Familial
More informationFamilial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
More informationColorectal Carcinoma Reporting in 2009
Colorectal Carcinoma Reporting in 2009 Overview Colorectal carcinoma- new and confusing AJCC TNM issues Wendy L. Frankel, M.D. Vice-Chair and Director of AP Department of Pathology The Ohio State University
More informationHereditary Non Polyposis Colorectal Cancer(HNPCC) From clinic to genetics
From clinic to genetics Question 1) Clinical pattern of inheritance of the HNPCC-Syndrome? Question 1) Clinical pattern of inheritance of the HNPCC-Syndrome? Autosomal dominant Question 2) Incidence of
More informationAgenda 8:30 AM. Jennifer L. Hunt
Agenda Topic Introduction Terence J. Colgan Jennifer L. Hunt Time 8:30 AM Pre-analytic Variables in Molecular Testing Philip A. Branton 8:40 AM Carcinoma of Unknown Primary Site Is Gene Expression Profiling
More informationPolicy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014
Medical Policy Genetic Testing for Colorectal Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date: October
More informationContent. Diagnostic approach and clinical management of Lynch Syndrome: guidelines. Terminology. Identification of Lynch Syndrome
of Lynch Syndrome: guidelines 17/03/2009 Content Terminology Lynch Syndrome Presumed Lynch Syndrome Familial Colorectal Cancer Identification of Lynch Syndrome Amsterdam II criteria Revised Bethesda Guidelines
More informationColorectal adenocarcinoma leading cancer in developed countries In US, annual deaths due to colorectal adenocarcinoma 57,000.
Colonic Neoplasia Remotti Colorectal adenocarcinoma leading cancer in developed countries In US, annual incidence of colorectal adenocarcinoma 150,000. In US, annual deaths due to colorectal adenocarcinoma
More informationCase Study. Overview. Deleterious MLH1 mutation detected on sequencing 10/16/2014
The Role of Next Generation Sequencing for Hereditary Cancer Syndromes: A Focus on Endometrial Cancer Laura J. Tafe, MD Assistant Professor of Pathology Assistant Director, Molecular Pathology Dartmouth-Hitchcock
More informationManagement of higher risk of colorectal cancer. Huw Thomas
Management of higher risk of colorectal cancer Huw Thomas Colorectal Cancer 41,000 new cases pa in UK 16,000 deaths pa 60% 5 year survival Adenoma-carcinoma sequence (Morson) Survival vs stage (Dukes)
More informationB Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696
Index Note: Page numbers of article titles are in boldface type. A Adenomatous polyposis, familial. See Familial adenomatous polyposis. Anal anastomosis, ileal-pouch, proctocolectomy with, in FAP, 591
More informationColonic polyps and colon cancer. Andrew Macpherson Director of Gastroentology University of Bern
Colonic polyps and colon cancer Andrew Macpherson Director of Gastroentology University of Bern Improtance of the problem of colon cancers - Epidemiology Lifetime risk 5% Incidence/10 5 /annum (US Detroit
More informationColon Cancer and Hereditary Cancer Syndromes
Colon Cancer and Hereditary Cancer Syndromes Gisela Keller Institute of Pathology Technische Universität München gisela.keller@lrz.tum.de Colon Cancer and Hereditary Cancer Syndromes epidemiology models
More informationCOLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014
COLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014 WENDY MCKINNON, MS, CGC CERTIFIED GENETIC COUNSELOR FAMILIAL CANCER PROGRAM UNIVERSIT Y OF VERMONT MEDICAL CENTER 1 CHARACTERISTICS
More informationColorectal Neoplasia. Dr. Smita Devani MBChB, MRCP. Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi
Colorectal Neoplasia Dr. Smita Devani MBChB, MRCP Consultant Physician and Gastroenterologist Aga Khan University Hospital, Nairobi Case History BT, 69yr male Caucasian History of rectal bleeding No change
More informationVENTANA MMR IHC Panel Interpretation Guide for Staining of Colorectal Tissue
VENTANA MMR IHC Panel Interpretation Guide for Staining of Colorectal Tissue VENTANA anti-mlh1 (M1) Mouse Monoclonal Primary Antibody VENTANA anti-pms2 (A16-4) Mouse Monoclonal Primary Antibody VENTANA
More informationCOLON CANCER GENETICS (FOR SURGEONS) Mark W. Arnold MD Chief, Division of Colon and Rectal Surgery Professor of Surgery The Ohio State University
COLON CANCER GENETICS (FOR SURGEONS) Mark W. Arnold MD Chief, Division of Colon and Rectal Surgery Professor of Surgery The Ohio State University 1. I am a surgeon; of course I have nothing to disclose.
More informationM. Azzam Kayasseh,Dubai,UAE
Thanks A Lot Prof. Linda + Prof. Ernst #drkayasseh_crc_rsm #WEO_CRCSC #UEGW17 @dubaiendoscopyforum @drkayasseh.care.to.cure Twenty World Areas Age-Standardized CRC Incidence Rates by Sex GLOBOCAN 2008
More informationMicrosatellite instability and other molecular markers: how useful are they?
Microsatellite instability and other molecular markers: how useful are they? Pr Frédéric Bibeau, MD, PhD Head, Pathology department CHU de Caen, Normandy University, France ESMO preceptorship, Barcelona,
More informationArthur Purdy Stout Society of Surgical Pathologists Companion Meeting. Microsatellite Instability and Serrated Adenomas in Common Practice
Arthur Purdy Stout Society of Surgical Pathologists Companion Meeting Microsatellite Instability and Serrated Adenomas in Common Practice United States and Canadian Academy of Pathology Annual Meeting
More informationGeneral Session 7: Controversies in Screening and Surveillance in Colorectal Cancer
General Session 7: Controversies in Screening and Surveillance in Colorectal Cancer Complexities of Pathological Assessment: Serrated Polyps/Adenomas Carolyn Compton, MD, PhD Professor of Life Sciences,
More informationCANCER. Inherited Cancer Syndromes. Affects 25% of US population. Kills 19% of US population (2nd largest killer after heart disease)
CANCER Affects 25% of US population Kills 19% of US population (2nd largest killer after heart disease) NOT one disease but 200-300 different defects Etiologic Factors In Cancer: Relative contributions
More informationGenetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationPathology perspective of colonic polyposis syndromes
Pathology perspective of colonic polyposis syndromes When are too many polyps too many? David Schaeffer Head and Consultant Pathologist, Department of Pathology and Laboratory Medicine, Vancouver General
More informationMismatch Repair Deficiency Testing for Patients with Colorectal Cancer: A Clinical and Cost-Effectiveness Evaluation
CADTH Optimal Use Report Mismatch Repair Deficiency Testing for Patients with Colorectal Cancer: A Clinical and Cost-Effectiveness Evaluation September 2015 Volume 5, Issue 3a PROSPERO Registration Number:
More informationCANCER GENETICS PROVIDER SURVEY
Dear Participant, Previously you agreed to participate in an evaluation of an education program we developed for primary care providers on the topic of cancer genetics. This is an IRB-approved, CDCfunded
More informationSpecial Section Hereditary Colorectal Cancer. What s New in Hereditary Colorectal Cancer? Jeremy R. Jass, MD, DSc, FRCPath, FRCPA
Special Section Hereditary Colorectal Cancer What s New in Hereditary Colorectal Cancer? Precancerous polyposes other than classic familial adenomatous polyposis and the condition hereditary nonpolyposis
More informationMismatch repair status, inflammation and outcome in patients with primary operable colorectal cancer
Mismatch repair status, inflammation and outcome in patients with primary operable colorectal cancer Park JH, Powell AG, Roxburgh CSD, Richards CH, Horgan PG, McMillan DC, Edwards J James Park Clinical
More informationAnatomic Molecular Pathology: An Emerging Field
Anatomic Molecular Pathology: An Emerging Field Antonia R. Sepulveda M.D., Ph.D. University of Pennsylvania asepu@mail.med.upenn.edu 2008 ASIP Annual Meeting Anatomic pathology (U.S.) is a medical specialty
More informationGenetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Policy Number: 2.04.08 Last Review: 1/2018 Origination: 1/2004 Next Review: 1/2019 Policy Blue Cross and Blue Shield of Kansas
More informationGeneral Surgery Grand Grounds
General Surgery Grand Grounds University of Colorado Health Sciences Center Case Presentation December 24, 2009 Adam Lackey, PGY-5 J.L. - 2111609 27 YO female with chief complaint of abdominal pain. PMHx:
More informationMultistep nature of cancer development. Cancer genes
Multistep nature of cancer development Phenotypic progression loss of control over cell growth/death (neoplasm) invasiveness (carcinoma) distal spread (metastatic tumor) Genetic progression multiple genetic
More informationThe molecular genetics of colorectal cancer
1 Department of Gastroenterology, North Middlesex University Hospital, London, UK 2 Institute of Molecular Genetics, Cardiff University 3 Department of Gastroenterology, Queen s Hospital Romford, London,
More informationDall istologia alla caratterizzazione biomolecolare
Il carcinoma ovarico: approccio multidisciplinare e prospettive terapeutiche Dall istologia alla caratterizzazione biomolecolare Anna Pesci Ospedale SC Don Calabria, Negrar anna.pesci@sacrocuore.it Ovarian
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Genetic Testing for Lynch Syndrome and Other Inherited Page 1 of 34 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Genetic Testing for Lynch Syndrome and Other
More informationGenetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Policy Number: Original Effective Date: MM.02.007 09/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration
More informationBRAF Testing In The Elderly: Same As in Younger Patients?
EGFR, K-RAS, K BRAF Testing In The Elderly: Same As in Younger Patients? Nadine Jackson McCleary MD MPH Gastrointestinal Oncology Dana-Farber/Harvard Cancer Care Boston, MA, USA Outline Colorectal cancer
More informationRisk of Colorectal Cancer (CRC) Hereditary Syndromes in GI Cancer GENETIC MALPRACTICE
Identifying the Patient at Risk for an Inherited Syndrome Sapna Syngal, MD, MPH, FACG Director, Gastroenterology Director, Familial GI Program Dana-Farber/Brigham and Women s Cancer Center Associate Professor
More informationYes when meets criteria below. Dean Health Plan covers when Medicare also covers the benefit.
Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post test genetic counseling is
More informationFROM EDUCATION TO TUMOUR CHARACTERISTICS IN COLORECTAL CANCER: AN ANALYSIS OF THE PATHWAYS
FROM EDUCATION TO TUMOUR CHARACTERISTICS IN COLORECTAL CANCER: AN ANALYSIS OF THE PATHWAYS By Parisa Airia A thesis submitted in conformity with the requirements for the degree of PhD Dalla Lana School
More informationIntroduction. Why Do MSI/MMR Analysis?
Clinical Significance Of MSI, KRAS, & EGFR Pathway In Colorectal Carcinoma UCSF & Stanford Current Issues In Anatomic Pathology Introduction Microsatellite instability and mismatch repair protein deficiency
More informationMr Chris Wakeman. General Surgeon University of Otago, Christchurch. 12:15-12:40 Management of Colorectal Cancer
Mr Chris Wakeman General Surgeon University of Otago, Christchurch 12:15-12:40 Management of Colorectal Cancer Bowel cancer Chris Wakeman Colorectal Surgeon Christchurch Sam Simon (Simpsons) Elizabeth
More informationFamily history and molecular features of children, adolescents, and young adults with colorectal carcinoma
1146 COLON CANCER Family history and molecular features of children, adolescents, and young adults with colorectal carcinoma C Durno, M Aronson, B Bapat, Z Cohen, S Gallinger... See end of article for
More informationResource impact report: Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)
Putting NICE guidance into practice Resource impact report: Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27) Published: February 2017 Summary Molecular testing strategies
More informationLYNCH SYNDROME: IN YOUR FACE BUT LOST IN SPACE (MOUNTAIN)!
LYNCH SYNDROME: IN YOUR FACE BUT LOST IN SPACE (MOUNTAIN)! Kathryn Singh, MPH, MS, LCGC Associate Clinical Professor Assistant Director, Graduate Program in Genetic Counseling Division of Genetic and Genomic
More informationGenetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Policy Number: 2.04.08 Last Review: 1/2019 Origination: 1/2004 Next Review: 1/2020 Policy Blue Cross and Blue Shield of Kansas
More informationDIAGNOSTICS ASSESSMENT PROGRAMME Diagnostics consultation document
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE DIAGNOSTICS ASSESSMENT PROGRAMME Diagnostics consultation document Molecular testing strategies for Lynch syndrome in The National Institute for Health
More informationBeyond the APC era Alternative pathways to CRC. Jeremy R Jass McGill University
Beyond the APC era Alternative pathways to CRC Jeremy R Jass McGill University Outline Limitations of APC model KRAS and serrated polyps CRC and CpG island methylation Serrated pathway to CRC Fusion pathways
More informationAssessment of Universal Mismatch repair (MMR) or Microsatellite Instability (MSI) testing in colorectal cancers.
Assessment of Universal Mismatch repair (MMR) or Microsatellite Instability (MSI) testing in colorectal cancers. Soheila Hamidpour MD, Madhusudhana S MD. MMR deficient colorectal tumors can be present
More informationColonic Polyp. Najmeh Aletaha. MD
Colonic Polyp Najmeh Aletaha. MD 1 Polyps & classification 2 Colorectal cancer risk factors 3 Pathogenesis 4 Surveillance polyp of the colon refers to a protuberance into the lumen above the surrounding
More informationcase report Reprinted from August 2013
Reprinted from August 2013 A 48-year-old woman with endometrial cancer Importance of screening for Lynch syndrome in patients with EC CAP TODAY and the Association for Molecular Pathology have teamed up
More informationGenetic Testing for Lynch Syndrome and Inherited Intestinal Polyposis Syndromes
Genetic Testing for Lynch Syndrome and Inherited Intestinal Polyposis Syndromes Policy Number: 2.04.08 Last Review: 1/2014 Origination: 1/2004 Next Review: 1/2015 Policy Blue Cross and Blue Shield of Kansas
More informationMolecular markers in colorectal cancer. Wolfram Jochum
Molecular markers in colorectal cancer Wolfram Jochum Biomarkers in cancer Patient characteristics Tumor tissue Normal cells Serum Body fluids Predisposition Diagnostic marker Specific diagnosis Prognostic
More informationHereditary Cancer Syndromes
Hereditary Cancer Syndromes Nicoleta Voian, MD, MPH Director Clinical Genetics Service Roswell Park Cancer Institute Nicoleta.Voian@Roswellpark.org February 28, 2017 Common Genetics Terms Gene: A hereditary
More informationThe Next Generation of Hereditary Cancer Testing
The Next Generation of Hereditary Cancer Testing Why Genetic Testing? Cancers can appear to run in families. Often this is due to shared environmental or lifestyle patterns, such as tobacco use. However,
More informationGenetic testing all you need to know
Genetic testing all you need to know Sue Clark Consultant Colorectal Surgeon, St Mark s Hospital, London, UK. Colorectal cancer Familial 33% Polyposis syndromes
More informationGenetic Testing for Familial Gastrointestinal Cancer Syndromes. C. Richard Boland, MD La Jolla, CA January 21, 2017
Genetic Testing for Familial Gastrointestinal Cancer Syndromes C. Richard Boland, MD La Jolla, CA January 21, 2017 Disclosure Information C. Richard Boland, MD I have no financial relationships to disclose.
More informationDiagnostics guidance Published: 22 February 2017 nice.org.uk/guidance/dg27
Molecular testing strategies for Lynch syndrome in people with colorectal cancer Diagnostics guidance Published: 22 February 2017 nice.org.uk/guidance/dg27 NICE 2018. All rights reserved. Subject to Notice
More informationChoice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair
Gut 1999;45:409 415 409 Molecular Oncology, Algernon Firth Institute of Pathology, School of Medicine, University of Leeds, Leeds, UK L Cawkwell H Murgatroyd F Sutherland L Haine S O Loughlin N Mapstone
More informationHereditary Gastric Cancer
Hereditary Gastric Cancer Dr Bastiaan de Boer Consultant Pathologist Department of Anatomical Pathology PathWest Laboratory Medicine, QE II Medical Centre Clinical Associate Professor School of Pathology
More informationSubject: Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
05-82000-31 Original Effective Date: 10/15/01 Reviewed: 10/25/18 Revised: 11/15/18 Subject: Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes THIS MEDICAL COVERAGE GUIDELINE
More informationGenetic Modifiers of Chemotherapy for Colorectal Cancer
Genetic Modifiers of Chemotherapy for Colorectal Cancer September 27, 2011 John M. Carethers, M.D. Professor of Internal Medicine University of Michigan 1,233,700 cases/year Worldwide ~146,000 cases/year
More informationHyperplastische Polyps Innocent bystanders?
Hyperplastische Polyps Innocent bystanders?? K. Geboes P th l i h O tl dk d Pathologische Ontleedkunde, KULeuven Content Historical Classification Relation Hyperplastic polyps carcinoma The concept cept
More informationGuidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer
s on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer Francis M. Giardiello, MD, 1 John I. Allen, 2 Jennifer E. Axilbund,
More informationIntroduction. Chapter 1
Introduction Chapter 1 1.1 Colorectal cancer Transformation from normal cell to cancer cell is thought to be a multi-step process involving the accumulation of genetic alterations in oncogenes, tumor
More informationGenetic Testing for Lynch Syndrome And Other Inherited Colon Cancer Syndromes
Genetic Testing for Lynch Syndrome And Other Inherited Colon Cancer Syndromes Policy Number: Original Effective Date: MM.02.007 09/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration
More informationASSESSMENT OF MLH1 PROMOTER METHYLATION IN ENDOMETRIAL CANCER USING PYROSEQUENCING TECHNOLOGY OBJECTIVES
ASSESSMENT OF MLH1 PROMOTER METHYLATION IN ENDOMETRIAL CANCER USING PYROSEQUENCING TECHNOLOGY Authors: Duilio Della Libera, Alessandra D Urso, Federica Modesti, Georgeta Florea, Marta Gobbato Hospital:
More informationWhat Pathology can tell us in the approach of localized colorectal cancer
What Pathology can tell us in the approach of localized colorectal cancer A/Prof Tony Lim Kiat Hon Department of Anatomical Pathology Singapore General Hospital ESMO 2017 Singapore Nov 1 2 Do we still
More informationReview Article Relationship between DNA Mismatch Repair Deficiency and Endometrial Cancer
SAGE-Hindawi Access to Research Molecular Biology International Volume 2011, Article ID 256063, 6 pages doi:10.4061/2011/256063 Review Article Relationship between DNA Mismatch Repair Deficiency and Kenta
More informationFAMILIAL COLORECTAL CANCER. Lyn Schofield Manager Familial Cancer Registry
FAMILIAL COLORECTAL CANCER Lyn Schofield Manager Familial Cancer Registry Cancer in WA 2004 4000 3500 ASPR, rate per 100,000 3000 2500 2000 1500 1000 Male incidence Female incidence Male mortality Female
More informationHyperplastic polyps in hereditary nonpolyposis colorectal cancer
4 Hyperplastic polyps in hereditary nonpolyposis colorectal cancer F E M Rijcken 1, T van der Sluis 2, H Hollema 2, J H Kleibeuker 1 Department of Gastroenterology 1 and Pathology 2, University Medical
More informationGenetic Testing for Lynch Syndrome
Genetic Testing for Lynch Syndrome MP9487 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes-as shown below Pre and post-test genetic counseling is
More informationNational Medical Policy
National Medical Policy Subject: Policy Number: Genetic Testing for Hereditary Nonpolyposis Colorectal Cancer (HNPCC) (Lynch Syndrome) NMP137 Effective Date*: April 2004 Updated: March 2017 This National
More informationGenetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory
2.04.08 Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date January 30, 2015 Original Policy Date October
More informationSessile Serrated Polyps
Årsmøtet i Den norske Patologforening 2014 Sessile Serrated Polyps Tor J. Eide Oslo Universitetssykehus The term serrated include a group of lesions with a sawtoothlike appearance of the crypts and the
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,350 108,000 1.7 M Open access books available International authors and editors Downloads Our
More informationMolecular aspects of HNPCC and identification of mutation carriers Niessen, Renee
University of Groningen Molecular aspects of HNPCC and identification of mutation carriers Niessen, Renee IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationColon Cancer Update Christie J. Hilton, DO
POMA Winter Conference Christie Hilton DO Medical Oncology January 2018 None Colon Cancer Numbers Screening (brief update) Practice changing updates in colon cancer MSI Testing Immunotherapy in Colon Cancer
More informationGENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS. Family Health Clinical Genetics. Clinical Genetics department
GENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS Full Title of Guideline: Author (include email and role): Division & Speciality: GUIDELINES FOR THE GENETIC MANAGEMENT OF A FAMILY
More informationDefective mismatch repair in the pathogenesis of low-grade appendiceal mucinous neoplasms and adenocarcinomas
& 2004 USCAP, Inc All rights reserved 0893-3952/04 $30.00 www.modernpathology.org Defective mismatch repair in the pathogenesis of low-grade appendiceal mucinous neoplasms and adenocarcinomas Joseph Misdraji
More informationHST.161 Molecular Biology and Genetics in Modern Medicine Fall 2007
MIT OpenCourseWare http://ocw.mit.edu HST.161 Molecular Biology and Genetics in Modern Medicine Fall 2007 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms.
More information